Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

USANA lowers guidance

This article was originally published in The Tan Sheet

Executive Summary

The direct-seller of nutritional, personal care and weight management products projects 2009 net sales of $390 million to $400 million, a 7 to 9 percent decrease from its 2008 revenues. USANA Health Sciences in February projected a 6 to 8 percent reduction in net sales for the year, accounting for foreign exchange losses. In its 2009 first quarter, the Salt Lake City-based company said April 28 it saw global net sales fall 4.2 percent to $97.3 million and North American revenues dropped 10.2 percent to $55.9 million. Though the firm pinned its declines largely on the negative impact of currency changes, net sales in North America were off by 2.2 percent excluding currency exchange for the three months ended April 4. CEO Dave Wentz expects the firm's associate ranks to grow and noted that the number of active North American associates grew slightly, 2.1 percent, over the year-ago quarter to 97,000

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS102880

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel